Storia in 5 fonti

Safety concerns spur FDA to again halt testing of Regenxbio gene therapy

Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo2 g fa

Safety concerns spur FDA to again halt testing of Regenxbio gene therapy

Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.

originale